This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (3)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Report of a Consensus Committee

Edward D. Frohlich, MD; Morton H. Maxwell, MD; Leslie Baer, MD; Haralambos Gavras, MD; John W. Hollifield, MD; Lawrence R. Krakoff, MD; Meyer D. Lifschitz, MD; Alexander Logan, MD; Eugene Poutasse, MD; David H. P. Streeten, MB

Arch Intern Med. 1982;142(8):1437-1440.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Almost 60 million adults in the United States have arterial hypertension. Most will be judged to have primary (essential) hypertension and will, therefore, be consigned to a lifetime of physician visits and antihypertensive drug therapy to prolong life and reduce cardiovascular morbidity. The longterm cost, unpleasant or adverse side effects of lifelong antihypertensive drug therapy, and high rate of lack of adherence (with the possible associated reduced benefit) are adequate reasons to search for secondary potentially curable causes of high BP, of which the most prevalent is renovascular hypertension.

Recently, saralasin acetate has been approved by the Food and Drug Administration for use as a diagnostic agent for the detection of angiotensin II-dependent (renin-mediated) hypertension. Most of the experimental and clinical studies of saralasin have been published in specialty journals,¹ so that many practicing physicians are unfamiliar with this drug or with its proper use. Therefore, a committee composed . . . [Full Text PDF of this Article]

Author Affiliations
Alton Ochsner Medical Foundation 1516 Jefferson Hwy New Orleans, LA 70121

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?